Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of nipocalimab versus IVIG in pregnant women at risk for fetal and neonatal alloimmune thrombocytopenia
MOH_2026-07-20_016946Phase 3Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in fetomaternal alloimmune thrombocytopenia (FMAIT) comparing Nipocalimab arm with IVIG plus prednisone arm (2 arms). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nipocalimabimmune globulinprednisone
03
Conditions
fetomaternal alloimmune thrombocytopenia (FMAIT)
Beyond the preview
Go deeper on MOH_2026-07-20_016946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-07-20_016946.